Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 4/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.56 |
| ▸ | MMP13 | P45452 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18914860 | 0.91 | PLK1 (0.73) | PLK1HPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL15223686 | 0.90 | PLK1 (0.67) | PLK1HPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL15223771 | 0.90 | PLK1 (0.67) | PLK1HPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL12441882 | 0.88 | PLK1 (0.73) | PLK1HPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL7921183 | 0.86 | TBXAS1 (0.58) | PLK1TSHRHTTSMN1; SMN2GAA | |
| SCHEMBL11962158 | 0.86 | PLK1 (1.00) | PLK1HPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL4751488 | 0.86 | PLK1 (0.75) | PLK1HPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL12839873 | 0.86 | PLK1 (0.87) | PLK1HPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL16329511 | 0.84 | PLK1 (0.63) | PLK1HPGDTSHRHTTSMN1; SMN2 | |
| SCHEMBL9629138 | 0.84 | PLK1 (0.73) | PLK1HPGDTSHRHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4121421-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | Novartis AG (CH) | 2023-01-25 | — | — | EP | claimed |
| WO-2021186324-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS AG (CH) | 2021-09-23 | — | — | WO | claimed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| EP-4395769-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2023-08-24 | — | — | US | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023031781-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2023-03-09 | — | — | WO | disclosed |
| EP-3458100-B1 | SELECTIVE REDUCTION OF CYSTEINE-ENGINEERED ANTIBODIES | BYONDIS BV (NL) | 2020-07-01 | — | — | EP | disclosed |
| US-20170320965-A1 | PAN-REACTIVE ANTIBODIES TO DUOCARMYCINS | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2017-11-09 | — | — | US | disclosed |
| WO-2017137628-A1 | SELECTIVE REDUCTION OF CYSTEINE-ENGINEERED ANTIBODIES | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2017-08-17 | — | — | WO | disclosed |
| WO-2008150231-A1 | NEW HETEROCYCLIC COMPOUNDS FOR TREATMENT OF RESPIRATORY, AIRWAY OR INFLAMMATORY DISORDERS | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265096-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, LDLR | PLK1 3265/4885HPGD 3815/4885TSHR 2711/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | PLK1 3178/4885HPGD 3855/4885TSHR 2628/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | PLK1 3265/4885HPGD 3815/4885TSHR 2711/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | PLK1 3178/4885HPGD 3855/4885TSHR 2628/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | PLK1 3178/4885HPGD 3855/4885TSHR 2628/4885 |
| US-20170320965-A1 | PAN-REACTIVE ANTIBODIES TO DUOCARMYCINS | GANAB, CNDP2, CD38 | PLK1 2826/4885HPGD 2297/4885TSHR 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.